<DOC>
	<DOCNO>NCT00991081</DOCNO>
	<brief_summary>The major purpose exploratory developmental study develop patient-centered feasible protocol communicate genetic data relates drug efficacy smoke cessation inpatient receive medication match individual genotype associate increase efficacy bupropion nicotine replacement therapy .</brief_summary>
	<brief_title>Behaviorally Enhanced Counseling Nicotine Dependence ( BEACON ) Trial .</brief_title>
	<detailed_description>Therefore , specific aim : Aim 1 : Conduct formative research develop refine clinical protocol multi-component smoking cessation intervention , ground extend parallel process model , consist pharmacogenetic treatment ( smoke cessation drug match individual smoker 's genotype ) genetic feedback ( delivery patient-centered , personalize genotype information predictive value smoke cessation treatment efficacy ) : We adapt , pilot-test , refine theoretically-grounded PGx smoking cessation intervention use formative interview 20 African-American European-ancestry smoker . Aim 2 : Conduct mixed-methods feasibility trial randomize treatment-seeking smoker pharmacogenetic ( PGx ) treatment combine genetic feedback ( GF ) vs. PGx treatment without GF smoke cessation examine feasibility newly develop protocol primary care set characterize psychological behavioral impact : Smokers ( N = 100 ) randomize GF vs. GF receive motivational interviewing ( standard care/SC ) PGx treatment . We assess impact GF time relapse , medication adherence , comprehensive assessment battery process cognitive , psychological , behavioral outcome . Finally , synthesize quantitative qualitative data revise protocol , generate hypothesizes , estimate effect size follow-up R01 submission .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Inclusion exclusion criterion participant formative interview ( Study A ) feasibility RCT ( Study B ) except Study A include African American European American smoker Study B include European American smoker . Inclusion criterion : Adults ( age 18 old ) Currently smoke least 10 cigarette per day Motivated quit smoking ( &gt; =5 10point Likert scale ) Have telephone Read speak English . Exclusion criterion : Any medical contraindication transdermal nicotine replacement therapy ( NRT ) sustainedrelease bupropion hydrochloride ( bupropion ) use base package label ( e.g. , bupropion , risk seizure ) DSMIV Axis I diagnosis ( nicotine dependence ) Subjects meet criterion current major depression , demonstrate evidence suicidal ideation screen refer treatment depression exclude study Must agree seek treatment smoke cessation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>pharmacogenetics</keyword>
	<keyword>genetic counseling</keyword>
	<keyword>genetic feedback</keyword>
	<keyword>nicotine replacement</keyword>
	<keyword>bupropion</keyword>
	<keyword>smoke cessation</keyword>
	<keyword>primary care</keyword>
	<keyword>telehealth</keyword>
	<keyword>motivational interviewing</keyword>
</DOC>